Objective. To describe the methodology for creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP) Material and methods. The registry included all patients admitted to the National Medical and Surgical Center named after N.I. Pirogov from April 6 to June 2, 2020 with suspected or confirmed coronavirus infection and community-acquired pneumonia. All patients’ data were taken from medical records. An additional survey of patients was performed (in the hospital or during the first 30 days of post-hospital period) in order to clarify data on risk factors, history of somatic and infectious diseases, pre-hospital drug therapy. At the outpatient stage, it is planned to collect data about the dynamics of clinical status and long-term outcomes in patients enrolled into the registry. For this purpose, a special survey of patients or their relatives during telephone contact 1-2, 6, 12 and 24 months after discharge from the hospital will be performed. Results. The registry included 1.130 patients (age 57.5±12.8 years, 51.2% men). COVID-19 was diagnosed in 60.7% of cases when PCR-tests were positive, and community-acquired pneumonia was confirmed in 94.2% of patents, cardiovascular diseases (CVD) were diagnosed in 52.9% of cases. Among chronic non-cardiac diseases the incidence of digestive diseases (22.1%) and diabetes (16.3%) was maximal, but those with bronchial asthma and anemia - were minimal (3.1 and 3.5%, respectively). CVDs or non- CVDs were revealed in 75.8% of cases. Data on the values of height and body weight were available in the medical records in 97% of cases, but the calculation of body mass index (BMI) was practically not used. The incidence of obesity according to clinical diagnosis was 6.1% while BMI≥30 kg/m was revealed in 35.2% of cases. Hydroxychloroquine was administrated in 84.3% of patients, anticoagulants - in 84.2%, antibiotics - in 70.0%, glucocorticoids - in 15.2%, antiviral drugs - in 5.9%, immune-suppressants - in 8.6% of patients. The rate of prescriptions of ACE-inhibitors/angiotensin receptor blockers (53.7%) and beta-blockers (45.6%) was bigger than those of other components of cardiovascular pharmacotherapy in 598 patients with CVD. The hospital mortality rate was 4.2%. Among the age group 65 years and older mortality (9.7%) was 6 times higher than among younger patients (1.6%). Patients who died were 16 years older than survivals. The proportion of patients with coronary artery disease, atrial fibrillation and chronic kidney disease was significantly bigger in non-survivals than in survivals (Odds Ratio after adjustment to age and sex was 2.2, 5.0 and 4.1, respectively; p